11.11.2019 • News

Solvay’s new Strategy Sets Growth Goals

CEO Ilham Kadri said the goal is to unleash the group’s full potential...
CEO Ilham Kadri said the goal is to unleash the group’s full potential through a “disciplined and differentiated allocation of resources, a tailored approach to customers and a repeatable cost and cash playbook.”

Belgian chemical producer Solvay has launched a new operating model called Solvay ONE to pursue its G.R.O.W forward strategy. CEO Ilham Kadri said the goal is to unleash the group’s full potential through a “disciplined and differentiated allocation of resources, a tailored approach to customers and a repeatable cost and cash playbook.”

Toward this goal, Solvay has realigned its businesses into three segments, Materials, Chemicals and Solutions, each with a distinct mandate.

In Materials, which comprises specialty polymers and composite materials – high-margin businesses with leading market positions – the group will prioritize investment and innovation, thereby leveraging synergy between the two units to create a leading thermoplastics platform.

For Chemicals, the Brussels group is depending on its position as a global leader in soda ash, peroxides and silica and the regional leadership of its Coatis and Rusvinyl businesses to deliver “resilient cash flows.” In future, it said it will invest “selectively” in these businesses.

Solvay’s new Solutions segment includes Novecare, Technology Solutions, Aroma and Special Chem, which operate in diverse niche markets. The strategy here is to optimize these businesses and leverage leadership positions while driving better returns and unlocking value.

On the financial side, the chemical producer has set a target to deliver €300-350 million in cost savings on a run rate basis by 2024. Effective management of pension liabilities, debt and working capital will generate approximately €500 million in additional cash flow cumulatively over the period, Kadri said.

Along the path to implementing its new strategy, Solvay has set midterm group targets, according to which underlying EBITDA should grow organically in the mid-single digit range from 2020-2024.

Interview

Navigating Uncertainty and Driving Innovation
Meeting Pharma’s Demand for Speed, Reliability, and Flexibility

Navigating Uncertainty and Driving Innovation

Axplora CCO Arul Ramadurai discusses navigating industry uncertainty, building strategic partnerships, and advancing flexible pharmaceutical manufacturing

Virtual Event

Outsourced Biomanufacturing
Strategic Outsourcing in Biopharmaceuticals

Outsourced Biomanufacturing

April 22, 2026 | Join biopharma professionals, CDMO leaders, and supply chain innovators for a virtual event exploring the future of outsourced biomanufacturing.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.